Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 6/20 | 0.62 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.38 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 6/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23974564 | 0.88 | OPRL1 (0.60) | OPRL1ESR2IDO1DGAT1SOAT1 | |
| SCHEMBL16132536 | 0.83 | OPRL1 (0.57) | OPRL1IDO1CYP17A1 | |
| SCHEMBL30127671 | 0.78 | OPRL1 (0.97) | OPRL1 | |
| SCHEMBL23974556 | 0.77 | OPRL1 (1.00) | OPRL1 | |
| SCHEMBL13347725 | 0.77 | OPRL1 (0.52) | OPRL1ESR2IDO1CYP17A1 | |
| SCHEMBL23974378 | 0.75 | OPRL1 (1.00) | OPRL1 | |
| SCHEMBL23974362 | 0.75 | OPRL1 (0.65) | OPRL1 | |
| SCHEMBL23974467 | 0.75 | OPRL1 (1.00) | OPRL1 | |
| SCHEMBL23974465 | 0.75 | OPRL1 (1.00) | OPRL1 | |
| SCHEMBL28564822 | 0.74 | OPRL1 (0.62) | OPRL1IDO1MAPTGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230144411-A1 | SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS | DART NEUROSCIENCE LLC | 2023-05-11 | — | — | US | disclosed |
| US-20230144411-A1 | SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS | DART NEUROSCIENCE LLC | 2023-05-11 | — | — | US | disclosed |
| EP-3759085-B1 | SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS | DART NEUROSCIENCE LLC (US) | 2022-12-14 | — | — | EP | disclosed |
| US-11365191-B2 | Substituted cyclohexyl compounds as NOP inhibiiors | DART NEUROSCIENCE, LLC (US) | 2022-06-21 | — | — | US | disclosed |
| US-20210340127-A1 | SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS | DART NEUROSCIENCE, LLC | 2021-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210340127-A1 | SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS | OPRL1, OPRK1, NOP56 | OPRL1 1/4885ESR2 765/4885IDO1 2151/4885 |
| US-11365191-B2 | Substituted cyclohexyl compounds as NOP inhibiiors | OPRL1, OPRK1, GAP43 | OPRL1 1/4885ESR2 337/4885IDO1 1113/4885 |
| US-20230144411-A1 | SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS | OPRL1, OPRK1, NOP56 | OPRL1 1/4885ESR2 765/4885IDO1 2151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.